Wugen Raises $172 Million to Advance Clinical Stage Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Multiple Solid Tumor Trials

Proceeds to advance clinical development of WU-NK-101 for relapsed/refractory AML, and initiate studies in solid tumor indications. Oversubscribed Series B co-led by Abingworth and Tybourne Capital Management, and joined by…

Read More
Siteman

Cell-based immunotherapy shows promise against melanoma

Source: SITEMAN Cancer Center, Julia Evangelou Strait, June 2021.

Read More

Wugen: deploying memory NK cells against cancer

Source: BIOCENTURY Wugen: deploying memory NK cells against cancer AND TURNING ALLOGENEIC CAR T CELLS AGAINST T CELL MALIGNANCIES BY LAUREN MARTZ, SENIOR EDITOR MAY 17, 2021 | 2:08 PM…

Read More

Wugen Appoints Daniel Kemp, Ph.D., as Chief Executive Officer

Biotech Executive and former Vice President of Research & Development at Takeda Pharmaceuticals brings notable expertise in cell therapies and strategic business development to the companyST. LOUIS, MO, and SAN…

Read More

The Development of Natural Killer Cells for Solid Tumor Treatment

Currently approved cellular therapies have been shown to effectively treat B-cell cancers, but there remains a significant unmet need for treating other cancers, including solid tumors.

Read More

Wugen Announces Exclusive Partnership Agreement With Alpha Biopharma in Asia For Cell Therapies to Treat Cancer

ST. LOUIS, MO, March 8, 2021 /PRNewswire/ – Wugen Inc., a clinical-stage biotechnology company developing novel universal natural killer (NK) and T-cell therapies for the treatment of cancer, today announced…

Read More

The Promise of Natural Killer Cells

Technology Networks, Ryan Sullivan, Wugen, March 2021

Read More